Whoa, did anyone see that email?

Today, the Company signed a Confidential Disclosure Agreement with the leading research and cancer treatment center in NYC for the licensing of a novel new compound. The Company was alerted to this compound by its scientific advisor, Dr. Samuel Danishefsky. The compound is interesting to Cellceutix in that it potentially treats illnesses associated with Cancer.  An example of such a drug would be Neupogen© by Amgen.  The compound is not a drug for tumor regression and possibly could create a whole new market for Cellceutix.  There is no assurance a full-fledged collaboration agreement will be executed with the Cancer Center.